Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Yiyao Cui,
†These authors have contributed equally to this work
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, the reference for (1-73) was incorrectly written as [1. Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, et al. Immune checkpoint blockade opens a new way to cancer immunotherapy.
2. Yang K, Li J, Sun Z, Zhao L, Bai C. Retreatment with immune checkpoint inhibitors in solid tumors: A systematic review.
3. Inthagard J, Edwards J, Roseweir AK. Immunotherapy: Enhancing the efficacy of this promising therapeutic in multiple cancers.
4. Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: Benefits and pulmonary toxicities.
5. Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, et al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: A systemic review and meta-analysis.
6. Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A. Paradigm shift in oncology: Targeting the immune system rather than cancer cells.
7. Gan J, Huang Y, Fang W, Zhang L. Research progress in immune checkpoint inhibitors for lung cancer in China.
8. Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting Ido1/Tdo and their downstream effectors.
9. Hoffmann D, Pilotte L, Stroobant V, Van den Eynde BJ. Induction of tryptophan 2,3-dioxygenase expression in human monocytic Leukemia/Lymphoma cell lines thp-1 and U937.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation.
11. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
12. Hoffmann D, Dvorakova T, Stroobant V, Bouzin C, Daumerie A, Solvay M, et al. Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers.
13. Dolsak A, Gobec S, Sova M. Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets.
14. Tina E, Prosen S, Lennholm S, Gasparyan G, Lindberg M, Gothlin Eremo A. Expression profile of the amino acid transporters Slc7a5, Slc7a7, Slc7a8 and the enzyme Tdo2 in basal cell carcinoma.
15. Greene LI, Bruno TC, Christenson JL, D’Alessandro A, Culp-Hill R, Torkko K, et al. A role for tryptophan-2,3-Dioxygenase in Cd8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma.
16. Smith LP, Bitler BG, Richer JK, Christenson JL. Tryptophan catabolism in epithelial ovarian carcinoma.
17. Liu Q, Zhai J, Kong X, Wang X, Wang Z, Fang Y, et al. Comprehensive analysis of the expression and prognosis for Tdo2 in breast cancer.
18. Terai M, Londin E, Rochani A, Link E, Lam B, Kaushal G, et al. Expression of tryptophan 2,3-dioxygenase in metastatic uveal melanoma.
19. Wang CY, Chiao CC, Phan NN, Li CY, Sun ZD, Jiang JZ, et al. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer.
20. Iwasaki T, Kohashi K, Toda Y, Ishihara S, Yamada Y, Oda Y. Association of pd-L1 and Ido1 expression with jak-stat pathway activation in soft-tissue leiomyosarcoma.
21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration.
22. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-Event data into meta-analysis.
23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
24. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials.
25. Zintzaras E, Ioannidis JP. Hegesma: Genome search meta-analysis and heterogeneity testing.
26. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test.
28. Tang Z, Kang B, Li C, Chen T, Zhang Z. Gepia2: An enhanced web server for Large-scale expression profiling and interactive analysis.
29. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. Webgestalt 2019: Gene set analysis toolkit with revamped uis and apis.
30. Sumitomo M, Takahara K, Zennami K, Nagakawa T, Maeda Y, Shiogama K, et al. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
31. Du L, Xing Z, Tao B, Li T, Yang D, Li W, et al. Both Ido1 and tdo contribute to the malignancy of gliomas
32. de Hosson LD, Takkenkamp TJ, Kats-Ugurlu G, Bouma G, Bulthuis M, de Vries EGE, et al. Neuroendocrine tumours and their microenvironment.
33. Chen X, Zang Y, Li D, Guo J, Wang Y, Lin Y, et al. Ido, tdo, and ahr overexpression is associated with poor outcome in diffuse Large b-cell lymphoma patients in the rituximab era.
34. Pham QT, Oue N, Sekino Y, Yamamoto Y, Shigematsu Y, Sakamoto N, et al. Tdo2 overexpression is associated with cancer stem cells and poor prognosis in esophageal squamous cell carcinoma.
35. Chen IC, Lee KH, Hsu YH, Wang WR, Chen CM, Cheng YW. Expression pattern and clinicopathological relevance of the indoleamine 2,3-dioxygenase 1/Tryptophan 2,3-dioxygenase protein in colorectal cancer.
36. Li S, Li L, Wu J, Song F, Qin Z, Hou L, et al. Tdo promotes hepatocellular carcinoma progression.
37. Wardhani LO, Matsushita M, Iwasaki T, Kuwamoto S, Nonaka D, Nagata K, et al. Expression of the Ido1/Tdo2-ahr pathway in tumor cells or the tumor microenvironment is associated with merkel cell polyomavirus status and prognosis in merkel cell carcinoma.
38. Riess C, Schneider B, Kehnscherper H, Gesche J, Irmscher N, Shokraie F, et al. Activation of the kynurenine pathway in human malignancies can be suppressed by the cyclin-dependent kinase inhibitor dinaciclib.
39. Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.
40. Marszalek-Grabska M, Walczak K, Gawel K, Wicha-Komsta K, Wnorowska S, Wnorowski A, et al. Kynurenine emerges from the shadows - current knowledge on its fate and function.
41. Kim M, Tomek P. Tryptophan: A rheostat of cancer immune escape mediated by immunosuppressive enzymes Ido1 and tdo.
42. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, et al. A Tdo2-ahr signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
43. Chen LB, Zhu SP, Liu TP, Zhao H, Chen PF, Duan YJ, et al. Cancer associated fibroblasts promote renal cancer progression through a Tdo/Kyn/Ahr dependent signaling pathway.
44. Paccosi S, Cecchi M, Silvano A, Fabbri S, Parenti A. Different effects of tryptophan 2,3-dioxygenase inhibition on sk-Mel-28 and hct-8 cancer cell lines.
45. Li L, Wang T, Li S, Chen Z, Wu J, Cao W, et al. Tdo2 promotes the emt of hepatocellular carcinoma through kyn-ahr pathway.
46. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
47. Reed MR, Maddukuri L, Ketkar A, Byrum SD, Zafar MK, Bostian ACL, et al. Inhibition of tryptophan 2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells.
48. Boros FA, Vecsei L. Immunomodulatory effects of genetic alterations affecting the kynurenine pathway.
49. Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, et al. Blockade of the ahr restricts a treg-macrophage suppressive axis induced by lkynurenine.
50. Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, et al. Tumor-expressed ido recruits and activates mdscs in a treg-dependent manner.
51. Gurczynski SJ, Pereira NL, Hrycaj SM, Wilke C, Zemans RL, Moore BB. Stem cell transplantation uncovers tdo-ahr regulation of lung dendritic cells in herpesvirus-induced pathology.
52. Qin Y, Wang N, Zhang X, Han X, Zhai X, Lu Y. Ido and tdo as a potential therapeutic target in different types of depression.
53. Perez-Castro L, Garcia R, Venkateswaran N, Barnes S, Conacci-Sorrell M. Tryptophan and its metabolites in normal physiology and cancer etiology.
54. Jia YQ, Yang B, Wen LL, Mu WX, Wang Z, Cheng B. Prognostic value of immune checkpoint molecules in head and neck cancer: A meta-analysis.
55. Yu CP, Fu SF, Chen X, Ye J, Ye Y, Kong LD, et al. The clinicopathological and prognostic significance of Ido1 expression in human solid tumors: Evidence from a systematic review and meta-analysis.
56. Wang S, Wu J, Shen H, Wang J. The prognostic value of ido expression in solid tumors: A systematic review and meta-analysis.
57. Chen S, Tan J, Zhang A. The ups, downs and new trends of Ido1 inhibitors.
58. Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S, et al. Targeting the Ido1 pathway in cancer: From bench to bedside.
59. Fiore A, Murray PJ. Tryptophan and indole metabolism in immune regulation.
60. Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting ido pathways to treat cancer: Lessons from the echo-301 trial and beyond.
61. Cui G, Lai F, Wang X, Chen X, Xu B. Design, synthesis and biological evaluation of indole-2-Carboxylic acid derivatives as Ido1/Tdo dual inhibitors.
62. Feng X, Shen P, Wang Y, Li Z, Bian J. Synthesis and
63. Pei Z, Mendonca R, Gazzard L, Pastor R, Goon L, Gustafson A, et al. Aminoisoxazoles as potent inhibitors of tryptophan 2,3-dioxygenase 2 (Tdo2).
64. Menke A. Is the hpa axis as target for depression outdated, or is there a new hope?
65. Hua S, Wang X, Chen F, Gou S. Novel conjugates with dual suppression of glutathione s-transferases and tryptophan-2,3-Dioxygenase activities for improving hepatocellular carcinoma therapy.
66. Andersen MH. The targeting of tumor-associated macrophages by vaccination.
67. Platten M, Nollen EAA, Rohrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
68. Hua S, Chen F, Wang X, Wang Y, Gou S. Pt(Iv) hybrids containing a tdo inhibitor serve as potential anticancer immunomodulators.
69. Zhou Q, Shi Y, Chen C, Wu F, Chen Z. A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-Dioxygenase in liver diseases.
70. Ye Z, Yue L, Shi J, Shao M, Wu T. Role of ido and tdo in cancers and related diseases and the therapeutic implications.
71. Li Y, Zhang S, Wang R, Cui M, Liu W, Yang Q, et al. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
72. Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
73. Badawy AA. Tryptophan: The key to boosting brain serotonin synthesis in depressive illness. J Psychopharmacol (2013) 27(10):878–93. doi: 10.1177/0269881113499209].
It should be [1. Ambros V. microRNAs: tiny regulators with great potential.
2. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 123(4):631-640. doi:
3. Lee, Y, Ahn, C, Han, J, Choi, H, Kim, J, Yim, J, et al. The nuclear RNase III Drosha initiates microRNA processing.
4. Ke XS, Liu CM, Liu DP, Liang CC. MicroRNAs: key participants in gene regulatory networks.
5. Tsuchiya S, Okuno Y, Tsujimoto G. MicroRNA: Biogenetic and functional mechanisms and involvements in cell differentiation and cancer.
6. Liu J. Control of protein synthesis and mRNA degradation by microRNAs.
7. Hu T, Shen H, Li J, Yang P, Gu Q, Fu Z. RFC2, a direct target of miR-744, modulates the cell cycle and promotes the proliferation of CRC cells.
8. Qian, W, Feng, Y, Li, J, Peng, W, Gu, Q, Zhang, Z, et al. Construction of ceRNA networks reveals differences between distal and proximal colon cancers.
9. Chen, F, Chu, L, Li, J, Shi, Y, Xu, B, Gu, J, et al. Hypoxia induced changes in miRNAs and their target mRNAs in extracellular vesicles of esophageal squamous cancer cells.
10. Ma, M, Li, J, Zhang, Z, Sun, J, Liu, Z, Zeng, Z, et al. The Role and Mechanism of microRNA-1224 in Human Cancer.
11. Li, J, Sun, J, Liu, Z, Zeng, Z, Ouyang, S, Zhang, Z, et al. The Roles of Non-Coding RNAs in Radiotherapy of Gastrointestinal Carcinoma.
12. Li, J, Feng, Y, Heng, D, Chen, R, Wang, Y, Xu, Z, et al. Circulating non-coding RNA cluster predicted the tumorigenesis and development of colorectal carcinoma.
13. Chen, F, Xu, B, Li, J, Yang, X, Gu, J, Yao, X, et al. Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma
14. Zhang, Y, Peng, C, Li, J, Zhang, D, Zhang, C, Jin, K, et al. Long non-coding RNA CCDC144NL-AS1 promotes cell proliferation by regulating the miR-363-3p/GALNT7 axis in colorectal cancer.
15. Li, J, Han, X, Gu, Y, Wu, J, Song, J, Shi, Z, et al.. LncRNA MTX2-6 Suppresses Cell Proliferation by Acting as ceRNA of miR-574-5p to Accumulate SMAD4 in Esophageal Squamous Cell Carcinoma.
16. Zhang, Z, Wang, S, Ji, D, Qian, W, Wang, Q, Li, J, et al. Construction of a ceRNA network reveals potential lncRNA biomarkers in rectal adenocarcinoma.
17. Zhang Y, Kong X, Zhang J, Wang X. Functional Analysis of Bronchopulmonary Dysplasia-Related Neuropeptides in Preterm Infants and miRNA-Based Diagnostic Model Construction.
18. Yan, Q, Ma, X, Shen, C, Cao, X, Feng, N, Qin, D, et al. Inhibition of Kaposi’s sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.
19. Yang X, Gao Y, Huang S, Su C, Wang J, Zheng N. Whole transcriptome-based ceRNA network analysis revealed ochratoxin A-induced compromised intestinal tight junction proteins through WNT/Ca(2+) signaling pathway.
20. Cao, Y, Deng, B, Zhang, S, Gao, H, Song, P, Zhang, J, et al.. Astragalus polysaccharide regulates brown adipogenic differentiation through miR-1258-5p-modulated cut-like homeobox 1 expression.
21. Fang Q, Liu H, Zhou A, Zhou H, Zhang Z. Circ_0046599 Promotes the Development of Hepatocellular Carcinoma by Regulating the miR-1258/RPN2 Network.
22. Zhang D, Zhang Y, Zhang X, Zhai H, Sun X, Li Y. Circ_0046600 promotes hepatocellular carcinoma progression
23. Lin, W, Lin, J, Li, J, Lin, Y, Chen, S, Wu, Y, et al. Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.
24. Hu, M, Wang, M, Lu, H, Wang, X, Fang, X, Wang, J, et al. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
25. Huang, WJ, Tian, XP, Bi, SX, Zhang, SR, He, TS, Song, LY, et al. The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis.
26. Shi, J, Chen, P, Sun, J, Song, Y, Ma, B, Gao, P, et al. MicroRNA-1258: An invasion and metastasis regulator that targets heparanase in gastric cancer.
27. Zhang W, Wu G, Sun P, Zhu Y, Zhang H. circ_SMAD2 regulate colorectal cancer cells proliferation through targeting miR-1258/RPN2 signaling pathway.
28. Zhang, Z, Li, J, Huang, Y, Peng, W, Qian, W, Gu, J, et al. Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC.
29. Hwang, JS, Jeong, EJ, Choi, J, Lee, YJ, Jung, E, Kim, SK, et al. MicroRNA-1258 Inhibits the Proliferation and Migration of Human Colorectal Cancer Cells through Suppressing CKS1B Expression.
30. Zhang H, Jiang S, Guo L, Li X. MicroRNA-1258, regulated by c-Myb, inhibits growth and epithelial-to-mesenchymal transition phenotype
31. Jia Z, Wang PS, Yang Y, Zhu DY, Wang ZH, Wang W. [LncRNA ASB16-AS1 regulates the proliferation, migration and invasion of esophageal cancer cells by targeting miR-1258].
32. Jiang, W, Wei, K, Pan, C, Li, H, Cao, J, Han, X, et al. MicroRNA-1258 suppresses tumour progression
33. Liu H, Chen X, Gao W, Jiang G. The expression of heparanase and microRNA-1258 in human non-small cell lung cancer.
34. Wang R, Liu H, Dong M, Huang D, Yi J. Exosomal hsa_circ_0000519 modulates the NSCLC cell growth and metastasis
35. Li W, Yang X, Shi C, Zhou Z. Hsa_circ_002178 Promotes the Growth and Migration of Breast Cancer Cells and Maintains Cancer Stem-like Cell Properties Through Regulating miR-1258/KDM7A Axis.
36. Sang, M, Li, A, Wang, X, Chen, C, Liu, K, Bai, L, et al. Identification of three miRNAs signature as a prognostic biomarker in breast cancer using bioinformatics analysis.
37. Zhao X. miR-1258 Regulates Cell Proliferation and Cell Cycle to Inhibit the Progression of Breast Cancer by Targeting E2F1.
38. Loginov VI, Burdennyy AM, Pronina IV, et al. [Novel miRNA genes hypermethylated in breast cancer].
39. Tang, D, Zhang, Q, Zhao, S, Wang, J, Lu, K, Song, Y, et al. The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer.
40. Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase.
41. Peng X, Zhang Y, Gao J, Cai C. MiR-1258 promotes the apoptosis of cervical cancer cells by regulating the E2F1/P53 signaling pathway.
42. Wang LQ, Kumar S, Calin GA, Li Z, Chim CS. Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification.
43. Wang LJ, Cai HQ. miR-1258: a novel microRNA that controls TMPRSS4 expression is associated with malignant progression of papillary thyroid carcinoma.
44. Qin, H, Gui, Y, Ma, R, Zhang, H, Guo, Y, Ye, Y, et al. miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma.
45. Liu, W, Zhou, Z, Zhang, Q, Rong, Y, Li, L, Luo, Y, et al. Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma.
46. Braga, EA, Loginov, VI, Burdennyi, AM, Filippova, EA, Pronina, IV, Kurevlev, SV, et al. Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer.
47. Filippova, EA, Loginov, VI, Burdennyi, AM, Braga, EA, Pronina, IV, Kazubskaya, TP, et al. Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems.
48. Loginov, VI, Burdennyy, AM, Filippova, EA, Pronina, IV, Kazubskaya, TP, Kushlinsky, DN, et al. [Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 Genes Associated with Ovarian Cancer Development and Metastasis].
49. Torres-Ferreira, J, Ramalho-Carvalho, J, Gomez, A, Menezes, FD, Freitas, R, Oliveira, J, et al. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.
50. Zhou, R, Jia, W, Gao, X, Deng, F, Fu, K, Zhao, T, et al. CircCDYL Acts as a Tumor Suppressor in Wilms’ Tumor by Targeting miR-145-5p.
51. Qi X, Chen X, Zhao Y, Chen J, Niu B, Shen B. Prognostic Roles of ceRNA Network-Based Signatures in Gastrointestinal Cancers.
52. Guo, L, Jia, L, Luo, L, Xu, X, Xiang, Y, Ren, Y, et al. Critical Roles of Circular RNA in Tumor Metastasis
53. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure.
54. Ming D, Zhang S, Liu X, Xu C, Zhang X. Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations.
55. Chaturvedi SS, Ramanan R, Waheed SO, Karabencheva-Christova TG, Christov CZ. Structure-function relationships in KDM7 histone demethylases.
56. Wang J, Li D, Zhao B, Kim J, Sui G, Shi J. Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression.
57. Yablonski D. Bridging the Gap: Modulatory Roles of the Grb2-Family Adaptor, Gads, in Cellular and Allergic Immune Responses.
58. Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
59. Zeng Q, Ma X, Song Y, Chen Q, Jiao Q, Zhou L. Targeting regulated cell death in tumor nanomedicines.
60. Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature.
61. Dong, H, Diao, H, Zhao, Y, Xu, H, Pei, S, Gao, J, et al. Overexpression of matrix metalloproteinase-9 in breast cancer cell lines remarkably increases the cell malignancy largely
62. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince.
63. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy.
64. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer.
65. Shi W, Huang Q, Xie J, Wang H, Yu X, Zhou Y. CKS1B as Drug Resistance-Inducing Gene-A Potential Target to Improve Cancer Therapy.
66. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion.
67. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition.
68. Li, J, Peng, W, Yang, P, Chen, R, Gu, Q, Qian, W, et al. MicroRNA-1224-5p Inhibits Metastasis and Epithelial-Mesenchymal Transition in Colorectal Cancer by Targeting SP1-Mediated NF-κB Signaling Pathways.
69. Liu, Y, Song, Y, Cao, M, Fan, W, Cui, Y, Cui, Y, et al. A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma.
70. Mayfosh AJ, Nguyen TK, Hulett MD. The Heparanase Regulatory Network in Health and Disease.
71. Kaur R, Deb PK, Diwan V, Saini B. Heparanase Inhibitors in Cancer Progression: Recent Advances.
72. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
73. Sharma GG, Okada Y, Von Hoff D, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.